Troncoso LL, Biancardi AL, de Moraes Jr HV, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol 2017; 23(32): 5836-5848 [PMID: 28932076 DOI: 10.3748/wjg.v23.i32.5836]
Corresponding Author of This Article
Leandro Lopes Troncoso, MD, Department of Ophthalmology, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil. leandroltroncoso@ufrj.br
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 28, 2017; 23(32): 5836-5848 Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5836
Ophthalmic manifestations in patients with inflammatory bowel disease: A review
Leandro Lopes Troncoso, Ana Luiza Biancardi, Haroldo Vieira de Moraes Jr, Cyrla Zaltman
Leandro Lopes Troncoso, Ana Luiza Biancardi, Haroldo Vieira de Moraes Jr, Department of Ophthalmology, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil
Cyrla Zaltman, Department of Internal Medicine, Gastroenterology Division, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil
Author contributions: Troncoso LL and Biancardi AL performed the literature review and wrote the paper; de Moraes Jr HV critically revised the article and provided photos; Zaltman C provided expertise and critical revision of the manuscript for important intellectual content; all authors approved the submitted version of the manuscript.
Conflict-of-interest statement: The authors report no conflict of interest regarding the publication of this paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Leandro Lopes Troncoso, MD, Department of Ophthalmology, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil. leandroltroncoso@ufrj.br
Telephone: +55-21-988878988 Fax: +55-21-33115645
Received: June 7, 2017 Peer-review started: June 8, 2017 First decision: June 22, 2017 Revised: June 29, 2017 Accepted: July 12, 2017 Article in press: July 12, 2017 Published online: August 28, 2017 Processing time: 81 Days and 7.2 Hours
Core Tip
Core tip: Among all inflammatory bowel disease (IBD) patients, ophthalmic inflammatory disorders occur in 0.3% to 13.0% of cases, 1.6%-5.4% among the ulcerative colitis and 3.5%-6.8% among the Crohn’s disease patients. Since asymptomatic inflammation of ocular tissues may occur, a routine ophthalmic follow-up is recommended in all IBD patients, mainly before changes in IBD therapy because some drugs may cause ocular adverse effects. Patients with chronic or recurrent use of systemic corticosteroids should be warned of the risk of cataracts and glaucoma. Patient awareness of possible eye involvement is important in improving understanding of their disease and health outcomes, supporting early diagnosis, which will contribute to success of the treatment.
